HC Wainwright Lowers Valneva (NASDAQ:VALN) Price Target to $18.00

Valneva (NASDAQ:VALN) had its price objective cut by equities researchers at HC Wainwright from $19.00 to $18.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 267.35% from the company’s previous close. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Price Performance

Valneva stock opened at $4.90 on Thursday. The stock’s fifty day moving average price is $4.29 and its two-hundred day moving average price is $5.78. The firm has a market cap of $398.17 million, a PE ratio of -37.69 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. Valneva has a one year low of $3.62 and a one year high of $9.50.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 as of its most recent filing with the Securities and Exchange Commission. 11.39% of the stock is owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.